Biogen Inc (Biogen) is a biopharmaceutical company. It discovers, develops, and delivers drugs for the treatment of serious neurological and neurodegenerative diseases, including multiple sclerosis (MS); Alzheimer’s disease and dementia; movement disorders and neuromuscular disorders such as spinal muscular atrophy and amyotrophic lateral sclerosis; ophthalmology; pain; neuropsychiatry; and acute neurology. It also manufactures and commercializes biosimilars of advanced biologics. The company markets its products under the brand names of VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Biogen's R&D arm focuses on understanding the underlying biology of diseases to discover and deliver treatments for patients with high unmet medical needs. The company applies its expertise in biologics and capabilities in small molecule, antisense, and other technologies to target specific medical needs where new or better treatments are needed. Biogen reinvests approximately US$2 billion annually from the sales of its commercialized products into its R&D engine, accelerating innovation in neurology, immunology, and rare diseases. The R&D units of Biogen include the Alzheimer's & Dementia and MS & Immunology Development Units, the Neuromuscular Development Unit, and the Immunology Research Unit. These units are responsible for leading disease area strategy, identifying high-value targets, and advancing promising candidates from preclinical to marketed stages. Biogen operates a global team of more than 1,300 experts in its R&D initiatives. The company has established business relationships and collaborations with other companies, universities, and medical research institutions to assist in the clinical development and commercialization of certain products and product candidates. The company has a diverse pipeline of potential breakthrough medicines in neurology, immunology, and rare diseases. In FY2025, the company spent US$1,753.2 million on its R&D activities, which as a percentage of revenue stood at 17.7%.